The Roots Analysis team is putting in its best effort to offer our clients / readers a reliable source of information, regarding how the pharmaceutical and biotech sectors are coping in the midst of the COVID-19 pandemic. Our intention is to generate realistic insights, based on a variety of factors, which are anticipated to influence both prevalent and future market dynamics. Reach out to us for any help.

Digital Solutions for Biomarkers Market by Content (Standalone Software Solutions and Combination Offerings), Purpose (Diagnosis, Early Screening, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Other Biomarkers), Therapeutic Area, Business Model, and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030

  • Lowest Price Guaranteed From USD 5,499

  • Published
    January 2021

  • Pages
    272

  • View Count
    4830

Example Insights

Digital-Solutions-for-Biomarkers-Market-Context Digital-Solutions-for-Biomarkers-Market-List-of-Digital-Solutions-for-Biomarkers Digital-Solutions-for-Biomarkers-Market-Digital-Solutions-for-Biomarkers Digital-Solutions-for-Biomarkers-Market-Competitiveness-Analysis
Digital-Solutions-for-Biomarkers-Market-Trend-Analysis Digital-Solutions-for-Biomarkers-Market-Global-Events-Analysis Digital-Solutions-for-Biomarkers-Market-Key-Investors Digital-Solutions-for-Biomarkers-Market-Partnerships-and-Collaborations
Digital-Solutions-for-Biomarkers-Market-Big-Pharma-Initiatives Digital-Solutions-for-Biomarkers-Market-Likely-Growth-Scenarios Digital-Solutions-for-Biomarkers-Market-Distribution-by-Purpose-of-Solution  

Overview

From periodically monitoring disease progression in patients to developing customized therapies based on genetic predisposition, biomarkers (which are specific indicators of biological events) have become an indispensable aspect of contemporary healthcare solutions / practices. Ongoing digitization efforts in the healthcare industry have led to the development of a number of digital solutions, which are capable of generating, collecting, and tracking medical data. From this data, details of anatomical, physiological, and molecular events, and even behavior-related patterns in humans, or digital biomarkers, have been acknowledged as viable inputs to explain, influence and / or predict health-related outcomes. Digital biomarkers are analyzed in silico, using advanced analytical algorithms and artificial intelligence (AI) enabled tools, and therefore, can be used to rapidly generate actionable insights and identify previously undetected biological events (obscured by the shortcomings of manual processes). In this context, regulatory bodies across the world have actually begun evaluating software as a medical device. Fundamentally, digital biomarkers are identified / measured using sensors and algorithms across the plethora of available connected medical devices and other health-focused software solutions. Moreover, the fact that the procurement / analysis of digital biomarkers are not limited to the physical confines of the clinical environment, presents new opportunities to revolutionize disease diagnosis, patient monitoring and clinical trial conduct. When combined with specific phenotypic signatures, digital biomarkers have demonstrated the potential to be used to generate insights related to esoteric medical fields, such as psychiatry and neurology. In fact, experts believe that future diagnostic / treatment protocols for certain mental health indications are likely to be underpinned by digital biomarkers, similar to how the management of diabetes and hypertension are underpinned by biochemical biomarkers.

In the current pandemic scenario, medical professionals are trying to identify digital biomarkers that can facilitate the successful screening / diagnosis of COVID-19 patients, remotely. For instance, the National Institutes of Health (NIH) has tasked physIQ with developing and validating an algorithm, which can use existing wearable biosensor-derived analytics (generated by the company’s pinpointIQ™ cloud platform) to discover a novel digital biomarker for COVID-19 associated decompensation. In this regard, it is worth noting that the development of tools to capture digital biomarkers and analyze them, requires multidisciplinary (including computer science and engineering, as well as neology and medicine) expertise. Currently, several successful start-ups claim to be involved in designing and developing the necessary software / hardware solutions for the abovementioned purposes. Most of these companies have also received significant capital investments to support their respective product development initiatives. One of the primary challenges encountered by innovators in this market is related to regulatory review. Digital biomarkers are subjected to the same level of regulatory scrutiny as their traditional counterparts. Moreover, there is an evident need for a systematic approach to assess the quality and utility of digitized renderings of biological events, in order to gauge their safety and efficacy in informing health-related decision making. Despite existing challenges, this niche, but emerging domain, is expected to evolve complementary to digital therapeutics, with pioneers in the field poised to benefit from the first-to-market advantage. Given the recent rise in partnership activity in this field, and the growing demand for remote diagnostic and therapeutic solutions (mostly influenced by the pandemic), we believe that the digital biomarkers market is likely to grow at a healthy pace over the next decade.

Scope of the Report

The “Digital Solutions for Biomarkers Market by Content of Solution (Standalone Software Solutions and Combination Offerings), Purpose of Solution (Diagnosis, Early Screening, Monitoring, and Predictive Insights), Type of Biomarker (Cognitive, Idiosyncratic, Physiological, Vocal, and Other Biomarkers), Therapeutic Area (Autoimmune Disorders, Cardiovascular Disorders, Infectious Disorders, Mental Health Problems, Neurological Disorders, Respiratory Disorders, Substance Use Disorders, and Other Disorders), Business Model (B2B and B2C), and by Key Geographical Regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World): Industry Trends and Global Forecasts, 2021-2030 ” report features an extensive study of the current landscape, offering an informed opinion on the likely adoption of digital solutions for biomarkers (either commercialized or under development) in the healthcare industry, over the next decade. The report features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. Amongst other elements, the report includes:

  • An overview of the current market landscape of digital solutions for biomarkers, including information on current status (approved, marketed, USFDA submission, research and development, proof-of-concept, and discovery), content of solution (combination offering of  software application / gaming solution + AI support or device or personal coach, and standalone software / gaming solution ), purpose of solution (diagnosis, early screening, monitoring and predictive insights), type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological, physiological, respiratory, vocal, and others ), target indication(s), therapeutic area(s), target population, and prescription requirement. In addition, it highlights the companies engaged in developing digital solutions for biomarkers, along with information on their year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters.
  • An in depth analysis of the contemporary market trends, presented using five schematic representations, including [A] a bubble analysis comparing the leading players engaged in the development of digital solutions for biomarkers, based on various parameters (such as product portfolio strength, type of biomarker and company size), [B] a grid representation illustrating the distribution of digital solutions for biomarkers based on their current status, content of solution and target therapeutic area, [C] an insightful tree map representation of digital solutions for biomarkers based on their therapeutic area and company size, [D] a world map representation highlighting the regional distribution of developer companies, and [E] a comparative grid representation to highlight the current and likely future market landscape based on status of development, type of biomarker and therapeutic area.  
  • Elaborate profiles of prominent players that are either currently engaged in developing or have developed digital solutions for biomarkers. Each company profile features a brief overview of the company (with information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolios, recent developments and an informed future outlook.
  • A detailed product competitiveness analysis of digital solutions for biomarkers taking into consideration several relevant parameters, such as current status, content of solution, purpose of solution, therapeutic area, and prescription requirement.
  • An analysis of the recent global events (summits / forums / conferences / annual meetings) that were organized for stakeholders engaged in this domain, highlighting the evolution of discussion topics related to digital solutions for biomarkers. The chapter also includes details on type of event, regional distribution, emerging agendas, popular organizers, and most active industry and non-industry players.
  • An elaborate analysis of the investments, including seed financing, venture capital financing, debt financing, grants / awards, made at various stages of development in companies that are engaged in this field, during the period 2012-2020 (till September). 
  • An analysis of the partnerships that have been inked by stakeholders in this domain, in the period between 2014 and 2020 (till September), covering marketing and distribution agreements, mergers / acquisitions, pilot programs, product / technology integration agreements, product / technology licensing agreements, product development agreements, product development and commercialization agreements, product evaluation agreements, and research and development agreements.
  • An analysis of the various digital solutions for biomarkers focused initiatives carried out by big pharma players (out of top 25 established pharmaceutical players), featuring [A] an analysis highlighting information on clinical research activity, funding, partnership activity, research publications, and participation in conferences, and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.
  • An insightful discussion on how the recent COVID-19 pandemic is likely to impact the overall digital solutions for biomarkers market, along with information on the key initiatives undertaken by big pharma players to overcome the challenges faced due to the pandemic.

One of the key objectives of the report was to estimate the existing market size and future opportunity for digital solutions for biomarkers developers over the next decade. Based on multiple parameters, likely adoption trends, and expected price variations for these products, we have provided an informed estimate of the evolution of the market for the period 2021-2030. The report also features the likely distribution of the current and forecasted opportunity within digital solutions for biomarkers market across [A] content of solution (combination offering of software application + device or AI, and standalone software applications), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World). In order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.

The opinions and insights presented in the report were influenced by discussions held with senior stakeholders in the industry. The report features detailed transcripts of interviews held with the following industry stakeholders: 

  • Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare)
  • Michael Seggev (Chief Commercial Officer, Vocalis Health)

All actual figures have been sourced and analyzed from publicly available information forums and primary research discussions. Financial figures mentioned in this report are in USD, unless otherwise specified.

Key Questions Answered

  • Who are the leading players engaged in digital solutions for biomarkers?
  • Which popular therapeutic areas are being targeted by digital solutions for biomarkers?
  • Which players are actively involved in organizing / participating in global events conducted within this domain?
  • What is the trend for capital investments in the digital solutions for biomarkers market?
  • Which partnership models are most commonly adopted by stakeholders engaged in this industry?
  • What type of strategies are being adopted by big pharma players engaged in this domain?
  • How is the recent COVID-19 pandemic likely to impact the overall digital solutions for biomarkers market?
  • What are the opportunities available for digital solutions for biomarkers in emerging markets?
  • How is the current and future opportunity likely to be distributed across key market segments?
  • What are the anticipated future trends related to digital solutions for biomarkers market?

Contents

Chapter Outlines

Chapter 2 is an executive summary of the key insights captured in our research. It offers a high-level view on the current state of digital solutions for biomarkers market and its likely evolution in the short-mid term and long term. 

Chapter 3 provides a general overview of the digital health sector, covering details related to the current and anticipated future trends in this domain, particularly for digital solutions for biomarkers. Further, it highlights the key concepts related to these modern solutions. The chapter also provides an overview of the various product development pathways adopted by the companies engaged in this domain. In addition, it features information on the prevalent Google Trends, during the period 2016-2020 (till December), as well as insights generated from recent news articles related to digital solutions for biomarkers, indicating the increasing popularity of this domain.

Chapter 4  includes a detailed analysis of the current market landscape of over 45 digital solutions for biomarkers, based on current status (approved, marketed, USFDA submission, research and development, proof-of-concept, and discovery), content of solution (combination offering of  software application / gaming solution + AI support or device or personal coach, and standalone software / gaming solution ), purpose of solution (diagnosis, early screening, monitoring, and predictive insights), type of biomarker (cognitive, idiosyncratic, molecular, neurophysiological, physiological, respiratory, vocal, and others ), target indication(s), therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), target population, and prescription requirement. In addition, the chapter highlights the companies engaged in developing digital solutions for biomarkers, along with information on year of establishment, company size, type of business model used (B2B and B2C) and location of headquarters. 

Chapter 5 highlights the contemporary market trends in five schematic representations, which include [A] a bubble analysis comparing the leading players engaged in the development of digital solutions for biomarkers, based on various parameters (such as product portfolio strength, type of biomarker and company size), [B] a grid representation illustrating the distribution of the digital solutions for biomarkers based on their current status, content of solution and therapeutic area, [C] an insightful tree map representation of the digital solutions for biomarkers, based on therapeutic area and company size, [D] a world map representation highlighting the regional distribution of developer companies, and [E] a comparative grid representation to highlight the current and likely future market landscape based on status of development, type of biomarker and therapeutic area.  

Chapter 6 features elaborate profiles of prominent players that are either currently engaged in developing or have developed digital solutions for biomarkers. Each company profile features a brief overview of the company (with information on its year of establishment, number of employees, location of headquarters and key members of the executive team), details related to their respective product portfolio, recent developments and an informed future outlook.

Chapter 7 presents a detailed product competitiveness analysis of digital solutions for biomarkers taking into consideration several parameters, such as current status, content of solution, purpose of solution, therapeutic area, and prescription requirement.

Chapter 8 provides an analysis of the recent global events (summits / forums / conferences / annual meetings) that were organized for stakeholders engaged in this domain, highlighting the evolution of discussion topics related to digital solutions for biomarkers. The chapter also includes details on type of event, regional distribution, emerging agendas, popular organizers, and most active industry and non-industry players.

Chapter 9 features an elaborate analysis of the investments, including seed financing, venture capital financing, debt financing, grants / awards, made at various stages of development in companies that are engaged in this field, during the period 2012-2020 (till September), highlighting the growing interest of the venture capital community and other strategic investors, in this domain. 

Chapter 10 features an in-depth analysis and discussion on the various partnerships inked between the players in this market, during the period, 2014 and 2020 (till September), covering marketing and distribution agreements, mergers / acquisitions, pilot programs, product / technology integration agreements,  product / technology licensing agreements, product development agreements, product development and commercialization agreements, product evaluation agreements, and research and development agreements.

Chapter 11 highlights the analysis of the various digital solutions for biomarkers focused initiatives carried out by big pharma players (out of top 25 established pharmaceutical players), featuring [A] an analysis highlighting information on clinical research activity, funding, partnership activity, research publications, and participation in conferences, and [B] a spider web representation of the individual competitiveness of the initiatives of big pharma players based on multiple relevant parameters.

Chapter 12 presents an insightful market forecast analysis, highlighting the likely growth of digital solutions for biomarkers market till 2030. We have segmented the market across [A] content of solution (combination offering of software application + device or AI, standalone software applications and other contents of solutions), [B] purpose of solution (diagnosis, early screening, monitoring and predictive insights), [C] type of biomarker (cognitive, idiosyncratic, physiological, vocal, and other biomarkers), [D] therapeutic area (autoimmune disorders, cardiovascular disorders, infectious disorders, mental health problems, neurological disorders, respiratory disorders, substance use disorders, and other disorders), [E] business model (B2B (healthcare providers, payers, employers and pharmaceutical companies) and B2C (patients and caregivers)), and [F] key geographical regions (North America, Europe, Asia-Pacific, Middle East and North Africa, and Rest of the World).

Chapter 13 highlights how the recent COVID-19 outbreak is likely to impact the overall digital biomarkers market. In addition, it features a brief discussion on the key initiatives undertaken by big pharma players to overcome the challenges faced due the pandemic

Chapter 14 summarizes the overall report, wherein we have mentioned all the key facts and figures described in the previous chapters. The chapter also highlights important evolutionary trends that were identified during the course of the study and are expected to influence the future of the digital solutions for biomarkers market.

Chapter 15 is a collection of interview transcripts of discussions held with various key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Edouard Gasser (Co-Founder and Chief Executive Officer, Tilak Healthcare), and Michael Seggev (Chief Commercial Officer, Vocalis Health).

Chapter 16 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.

Chapter 17 is an appendix, which contains the list of companies and organizations mentioned in the report.

Table Of Contents

 1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Key Questions Answered
1.4. Chapter Outlines

2. EXECUTIVE SUMMARY

3. INTRODUCTION 
3.1 Chapter Overview
3.2. Overview of Digital Biomarkers 
3.2.1 Classification of Digital Biomarkers
3.2.2 Key Advantages and Limitations

3.3. Digital Biomarker-related Product Development and Commercialization Path
3.3.1. Product Discovery and Development
3.3.2. Validation and Regulatory Submissions
3.3.3. Distribution and Marketing 

3.4. Prevalent Trends Related to Digital Biomarkers
3.4.1. Emerging Focus Areas
3.4.2. Key Historical Trends
3.4.3. Geographical Activity

4 . MARKET LANDSCAPE
4.1. Chapter Overview
4.2. Digital Solutions for Biomarkers: Overall Market Landscape
4.2.1. Analysis by Current Status
4.2.2. Analysis by Content of Solution
4.2.3. Analysis by Purpose of Solution
4.2.4. Analysis by Type of Biomarker
4.2.5. Analysis by Target Indication(s)
4.2.6. Analysis by Therapeutic Area 
4.2.7. Analysis by Target Population
4.2.8. Analysis by Prescription Requirement

4.3. Digital Solutions for Biomarkers: Developer Landscape
4.3.1. Analysis by Year of Establishment
4.3.2. Analysis by Company Size
4.3.3. Analysis by Type of Business Model Used
4.3.4 Analysis by Location of Headquarters

4.4. Leading Developers: Analysis by Number of Digital Solutions for Biomarker 
4.5. Digital Solutions for Biomarkers: Information on Additional Players

5. KEY INSIGHTS
5.1. Chapter Overview
5.2. 4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
5.3. Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
5.4. Treemap Representation: Analysis by Therapeutic Area and Company Size
5.5. World Map Representation: Analysis by Location of Headquarters
5.6. Current and Future Market Landscape Trends Analysis

6. COMPANY PROFILES
6.1. Chapter Overview
6.2. Acculi Labs
6.2.1 Company Overview
6.2.2. Product Portfolio
6.2.3. Recent Developments and Future Outlook

6.3. Canary Health Technologies
6.3.1. Company Overview
6.3.2. Product Portfolio
6.3.3. Recent Developments and Future Outlook

6.4. Empatica
6.4.1. Company Overview
6.4.2. Product Portfolio
6.4.3. Recent Developments and Future Outlook

6.5 IXICO
6.5.1. Company Overview
6.5.2. Product Portfolio
6.5.3. Recent Developments and Future Outlook 

6.6. Kinsa
6.6.1. Company Overview
6.6.2. Product Portfolio
6.6.3. Recent Developments and Future Outlook 

6.7. Progentec Diagnostics
6.7.1. Company Overview
6.7.2. Product Portfolio
6.7.3. Recent Developments and Future Outlook 

6.8. Vocalis Health
6.8.1. Company Overview
6.8.2. Product Portfolio
6.8.3 Recent Developments and Future Outlook

7. PRODUCT COMPETITIVENESS ANALYSIS
7.1. Chapter Overview
7.2. Key Parameters and Methodology
7.3. Product Competitiveness Analysis
7.3.1. Product Competitiveness Analysis: Idiosyncratic Biomarkers
7.3.2. Product Competitiveness Analysis: Physiological Biomarkers
7.3.3. Product Competitiveness Analysis: Vocal Biomarkers
7.3.4. Product Competitiveness Analysis: Other Biomarkers

8 . GLOBAL EVENT ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology

8.3. Global Events Related to Digital Biomarkers 
8.3.1. Analysis by Year of Occurrence
8.3.2. Analysis by Event Platform
8.3.3. Analysis by Geography
8.3.4. Analysis by Type of Event
8.3.5. Evolutionary Trend in Key Agenda / Event Agenda
8.3.6. Most Active Event Organizers
8.3.7. Most Active Players in Terms of Event Participation
8.3.8. Analysis by Seniority Level of Participants

9. FUNDING AND INVESTMENT ANALYSIS
9.1. Chapter Overview
9.2. Types of Funding

9.3. Digital Solutions for Biomarkers: Funding and Investment Analysis
9.3.1. Analysis by Number of Funding Instances
9.3.2. Analysis by Amount Invested
9.3.3. Analysis by Type of Funding
9.3.4. Analysis by Type of Biomarker
9.3.5. Analysis by Therapeutic Area
9.3.6. Analysis by Geography 
9.3.7. Most Active Players: Analysis by Number of Instances
9.3.8. Most Active Players: Analysis by Amount Invested
9.3.9. Most Active Investors: Analysis by Number of Instances

9.4 Concluding Remarks

10. PARTNERSHIPS AND COLLABORATIONS 
10.1. Chapter Overview
10.2. Partnership Models

10.3. Digital Solutions for Biomarkers: Recent Partnerships and Collaborations 
10.3.1. Analysis by Year of Partnership
10.3.2. Analysis by Type of Partnership
10.3.2.1. Analysis by Type of Partnership and Year of Partnership
10.3.2.2. Analysis by Type of Partnership and Company Size

10.3.3. Analysis by Type of Partner
10.3.3.1. Analysis by Type of Partner and Year of Partnership
10.3.3.2. Analysis by Type of Partner and Type of Partnership
10.3.3.3. Analysis by Type of Partner and Company Size

10.3.4. Analysis by Type of Biomarker
10.3.4.1. Analysis by Type of Biomarker and Year of Partnership
10.3.4.2. Analysis by Type of Biomarker and Type of Partnership

10.3.5. Analysis by Therapeutic Area
10.3.5.1. Analysis by Therapeutic Area and Year of Partnership
10.3.5.2 Analysis by Therapeutic Area and Type of Partner

10.3.6. Most Active Players: Analysis by Number of Partnerships
10.3.7. Regional Analysis
10.3.8. Intercontinental and Intracontinental Agreements

11. BIG PHARMA INITIATIVES
11.1. Chapter Overview
11.2. Scope and Methodology

11.3. Digital Biomarker-related Initiatives of Big Pharma Players
11.3.1. Clinical Research Activity
11.3.2. Partnership Activity
11.3.3. Funding and Investments
11.3.4. Participation in Global Events
11.3.5. Research Publications

11.4. Benchmark Analysis of Big Pharmaceutical Players
11.4.1. Spider Web Analysis: Company A
11.4.2. Spider Web Analysis: Company B
11.4.3. Spider Web Analysis: Company C
11.4.4. Spider Web Analysis: Company D
11.4.5. Spider Web Analysis: Company E
11.4.6. Spider Web Analysis: Company F
11.4.8. Spider Web Analysis: Company G
11.4.8. Spider Web Analysis: Company H
11.4.9. Spider Web Analysis: Company I
11.4.10. Spider Web Analysis: Company J
11.4.11. Spider Web Analysis: Company K
11.4.12. Spider Web Analysis: Company L
11.4.13. Spider Web Analysis: Company M

12. MARKET FORECAST
12.1. Chapter Overview
12.2. Forecast Methodology and Key Assumptions
12.3. Digital Solutions for Biomarkers Market, 2021-2030

12.4. Digital Solutions for Biomarkers Market: Distribution by Content of Solution
12.4.1. Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030
12.4.2. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support), 2021-2030
12.4.3. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + Device), 2021-2030
12.4.4. Digital Solutions for Biomarkers Market for Combination Offering (Software Application + AI Support + Device), 2021-2030
12.4.5. Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030

12.5. Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution
12.5.1. Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030
12.5.2. Digital Solutions for Biomarkers Market for Early Screening, 2021-2030
12.5.3. Digital Solutions for Biomarkers Market for Monitoring, 2021-2030
12.5.4. Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030

12.6. Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker
12.6.1. Digital Solutions for Cognitive Biomarkers Market, 2021-2030
12.6.2. Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030
12.6.3. Digital Solutions for Physiological Biomarkers Market, 2021-2030
12.6.4. Digital Solutions for Vocal Biomarkers Market, 2021-2030
12.6.5. Digital Solutions for Other Biomarkers Market, 2021-2030

12.7. Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area
12.7.1. Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030
12.7.2. Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030
12.7.3. Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030
12.7.4. Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030
12.7.5. Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030
12.7.6. Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030
12.7.7. Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030
12.7.8. Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030

12.8. Digital Solutions for Biomarkers Market: Distribution by Business Model 
12.8.1. Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030
12.8.2. Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030

12.9. Digital Solutions for Biomarkers Market: Distribution by Key Geographical Regions
12.9.1. Digital Solutions for Biomarkers Market in North America, 2021-2030
12.9.2. Digital Solutions for Biomarkers Market in Europe, 2021-2030
12.9.3. Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030
12.9.4. Digital Solutions for Biomarkers Market in Middle East and North Africa (MENA), 2021-2030
12.9.5. Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030

12.10. Concluding Remarks

13. IMPACT OF COVID-19 PANDEMIC ON DIGITAL SOLUTIONS FOR BIOMARKERS MARKET
13.1. Chapter Overview
13.2. Impact of COVID-19 Pandemic on Digital Solutions for Biomarkers Market
13.2.1. Impact on Future Market Opportunity for Digital Solutions for Biomarkers  
13.3. Current Opinions and Key Initiatives of Key Players

13.4. Recuperative Strategies for Developer Businesses
13.4.1. Strategies for Implementation in the Short / Mid Term
13.4.2. Strategies for Implementation in the Long Term

14. CONCLUSION
14.1. Chapter Overview
14.2. Key Takeaways

15. EXECUTIVE INSIGHTS
15.1. Chapter Overview
15.2. Tilak Healthcare
15.2.1. Company Snapshot
15.2.2. Interview Transcript: Edouard Gasser, Co-Founder and Chief Executive Officer

15.3. Vocalis Health
15.3.1. Company Snapshot
15.3.2. Interview Transcript: Michael Seggev, Chief Commercial Officer

16. APPENDIX I: TABULATED DATA

17. APPENDIX II: LIST OF COMPANIES AND ORGANIZATION

List Of Figures

Figure 3.1 Types of Digital Biomarkers
Figure 3.2 Types of Biomarkers / Signals captured by Digital Solutions for Biomarkers
Figure 3.3 Key Advantages and Limitations for Digital Biomarkers
Figure 3.4 Google News: Emerging Focus Areas
Figure 3.5 Google Trends: Historical Timeline
Figure 3.6 Google Trends: Geographical Activity
Figure 4.1 Digital Solutions for Biomarkers: Distribution by Current Status
Figure 4.2 Digital Solutions for Biomarkers: Distribution by Launch Year
Figure 4.3 Digital Solutions for Biomarkers: Distribution by Content of Solution
Figure 4.4 Digital Solutions for Biomarkers: Distribution by Purpose of Solution
Figure 4.5 Digital Solutions for Biomarkers: Distribution by Type of Biomarker
Figure 4.6 Digital Solutions for Biomarkers: Distribution by Purpose of Solution and Type of Biomarker
Figure 4.7 Digital Solutions for Biomarkers: Distribution by Target Indication(s)
Figure 4.8 Digital Solutions for Biomarkers: Distribution by Therapeutic Area
Figure 4.9 Digital Solutions for Biomarkers: Distribution by Target Population
Figure 4.10 Digital Solutions for Biomarkers: Distribution by Prescription Requirement
Figure 4.11 Digital Solutions for Biomarkers Developers: Distribution by Year of Establishment
Figure 4.12 Digital Solutions for Biomarkers Developers: Distribution by Company Size
Figure 4.13 Digital Solutions for Biomarkers Developers: Distribution by Type of Business Model Used
Figure 4.14 Digital Solutions for Biomarkers Developers: Distribution by Location of Headquarters
Figure 4.15 Digital Solutions for Biomarkers Developers: Leading Developers Based on Number of Digital Solutions for Biomarkers
Figure 5.1 4D Bubble Analysis: Distribution by Portfolio Strength, Type of Biomarker and Company Size
Figure 5.2 Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
Figure 5.3 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Figure 5.4 World Map Representation: Analysis by Location of Headquarters
Figure 5.5 Current and Future Market Landscape Trend Analysis: Distribution by Status of Development, Type of Biomarker and Therapeutic Area
Figure 7.1 Product Competitiveness Analysis: Idiosyncratic Biomarkers
Figure 7.2 Product Competitiveness Analysis: Physiological Biomarkers
Figure 7.3 Product Competitiveness Analysis: Vocal Biomarkers
Figure 7.4 Product Competitiveness Analysis: Other Biomarkers
Figure 8.1 Global Events Analysis: Cumulative Year-Wise Trend, 2016-H1 2021
Figure 8.2 Global Events Analysis: Distribution by Event Platform
Figure 8.3 Global Events Analysis: Distribution by Geography
Figure 8.4 Global Events Analysis: Distribution by Location
Figure 8.5 Global Events Analysis: Distribution by Type of Event
Figure 8.6 Global Events Analysis: Evolutionary Trend of Key Agendas
Figure 8.7 Global Events Analysis: Historical Trend of Key Agendas, 2016-H1 2021
Figure 8.8 Global Events Analysis: Most Active Event Organizers
Figure 8.9 Global Events Analysis: Most Active Industry Players Based on Event Participation
Figure 8.10 Global Events Analysis: Most Active Non-Industry Players Based on Event Participation
Figure 8.11 Global Event Analysis: Distribution by Designations of Event Participants
Figure 9.1 Funding and Investments Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding
Figure 9.2 Funding and Investments Analysis: Cumulative Year-wise Distribution of Funding Instances, 2012 – Q3 2020
Figure 9.3 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.4 Funding and Investments Analysis: Distribution of Instances by Type of Funding, 2012 - Q3 2020
Figure 9.5 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding, 2012 - Q3 2020
Figure 9.6 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding and Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.7 Funding and Investments Analysis: Summary of Amount Invested (USD Million), 2012 - Q3 2020
Figure 9.8 Funding and Investments Analysis: Distribution of Instances by Type of Biomarker, 2012 - Q3 2020
Figure 9.9 Funding and Investments Analysis: Distribution of Total Amount Invested by Type of Biomarker, 2012 – Q3 2020 (USD Million)
Figure 9.10 Funding and Investments Analysis: Year-Wise Distribution of Instances by Type of Biomarker, 2012 – Q3 2020
Figure 9.11 Funding and Investments Analysis: Cumulative Amount Invested by Type of Biomarker, 2012 - Q3 2020 (USD Million)
Figure 9.12 Funding and Investments Analysis: Distribution of Instances by Therapeutic Area, 2012 – Q3 2020
Figure 9.13 Funding and Investments Analysis: Distribution of Total Amount Invested by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Figure 9.14 Funding and Investment Analysis: Distribution by Geography
Figure 9.15 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2012 – Q3 2020 (USD Million)
Figure 9.16 Funding and Investment Analysis: Most Active Players Based on Number of Funding Instances, 2012 – Q3 2020
Figure 9.17 Funding and Investment Analysis: Most Active Players Based on Total Amount Raised, 2012 – Q3 2020 (USD Million)
Figure 9.18 Funding and Investment Analysis: Most Active Investors Based on Number of Funding Instances
Figure 9.19 Funding and Investment Summary, 2012 – Q3 2020 (USD Million)
Figure 10.1 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014 - Q3 2020
Figure 10.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 10.3 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Figure 10.4 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Figure 10.5 Partnerships and Collaborations: Distribution by Type of Partner
Figure 10.6 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Figure 10.7 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Figure 10.8 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Figure 10.9 Partnerships and Collaborations: Distribution by Type of Biomarker
Figure 10.10 Partnerships and Collaborations: Year-Wise Trend by Type of Biomarker
Figure 10.11 Partnerships and Collaborations: Distribution by Type of Biomarker and Type of Partnership
Figure 10.12 Partnerships and Collaborations: Distribution by Therapeutic Area
Figure 10.13 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Figure 10.14 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Figure 10.15 Most Active Players: Distribution by Number of Partnerships
Figure 10.16 Partnerships and Collaborations: Regional Distribution
Figure 10.17 Partnerships and Collaborations: Country-wise Distribution
Figure 10.18 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 11.1 Big Pharma Initiatives: Heat Map Distribution of Top Pharmaceutical Companies
Figure 11.2 Big Pharma Initiatives: Distribution by Number of Clinical Trials
Figure 11.3 Big Pharma Initiatives: Distribution by Number of Collaborations
Figure 11.4 Big Pharma Initiatives: Distribution by Amount of Funding (USD Million)
Figure 11.5 Big Pharma Initiatives: Distribution by Participation in Global Events
Figure 11.6 Big Pharma Initiatives: Distribution by Number of Research Publications
Figure 11.7 Spider Web Analysis: Company A
Figure 11.8 Spider Web Analysis: Company B
Figure 11.9 Spider Web Analysis: Company C
Figure 11.10 Spider Web Analysis: Company D
Figure 11.11 Spider Web Analysis: Company E
Figure 11.12 Spider Web Analysis: Company F
Figure 11.13 Spider Web Analysis: Company G
Figure 11.14 Spider Web Analysis: Company H
Figure 11.15 Spider Web Analysis: Company I
Figure 11.16 Spider Web Analysis: Company J
Figure 11.17 Spider Web Analysis: Company K
Figure 11.18 Spider Web Analysis: Company L
Figure 11.19 Spider Web Analysis: Company M
Figure 12.1 Overall Digital Solutions for Biomarkers Market, 2021-2030 (USD Million)
Figure 12.2 Global Digital Solutions for Biomarkers Market: Distribution by Content of Solution, 2021 and 2030
Figure 12.3 Digital Solutions for Biomarkers Market for Standalone Software Applications, 2021-2030 (USD Million)
Figure 12.4 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + AI Support), 2021-2030 (USD Million)
Figure 12.5 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + Device), 2021-2030 (USD Million)
Figure 12.6 Digital Solutions for Biomarkers Market for Other Content of Solutions, 2021-2030 (USD Million)
Figure 12.7 Global Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution, 2021 and 2030
Figure 12.8 Digital Solutions for Biomarkers Market for Diagnosis, 2021-2030 (USD Million)
Figure 12.9 Digital Solutions for Biomarkers Market for Early Screening, 2021-2030 (USD Million)
Figure 12.10 Digital Solutions for Biomarkers Market for Monitoring, 2021-2030 (USD Million)
Figure 12.11 Digital Solutions for Biomarkers Market for Predictive Insights, 2021-2030 (USD Million)
Figure 12.13 Global Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker, 2021 and 2030
Figure 12.14 Digital Solutions for Cognitive Biomarkers Market, 2021-2030 (USD Million)
Figure 12.15 Digital Solutions for Idiosyncratic Biomarkers Market, 2021-2030 (USD Million)
Figure 12.16 Digital Solutions for Physiological Biomarkers Market, 2021-2030 (USD Million)
Figure 12.17 Digital Solutions for Vocal Biomarkers Market, 2021-2030 (USD Million)
Figure 12.18 Digital Solutions for Other Biomarkers Market, 2021-2030 (USD Million)
Figure 12.19 Global Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area, 2021 and 2030
Figure 12.20 Digital Solutions for Biomarkers Market for Autoimmune Disorders, 2021-2030 (USD Million)
Figure 12.21 Digital Solutions for Biomarkers Market for Cardiovascular Disorders, 2021-2030 (USD Million)
Figure 12.22 Digital Solutions for Biomarkers Market for Infectious Disorders, 2021-2030 (USD Million)
Figure 12.23 Digital Solutions for Biomarkers Market for Mental Health Problems, 2021-2030 (USD Million)
Figure 12.24 Digital Solutions for Biomarkers Market for Neurological Disorders, 2021-2030 (USD Million)
Figure 12.25 Digital Solutions for Biomarkers Market for Respiratory Disorders, 2021-2030 (USD Million)
Figure 12.26 Digital Solutions for Biomarkers Market for Substance Use Disorders, 2021-2030 (USD Million)
Figure 12.27 Digital Solutions for Biomarkers Market for Other Disorders, 2021-2030 (USD Million)
Figure 12.28 Global Digital Solutions for Biomarkers Market: Distribution by Business Model, 2021 and 2030
Figure 12.29 Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), 2021-2030 (USD Million)
Figure 12.30 Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), 2021-2030 (USD Million)
Figure 12.31 Global Digital Solutions for Biomarkers Market: Distribution by Geography, 2021 and 2030
Figure 12.32 Digital Solutions for Biomarkers Market in North America, 2021-2030 (USD Million)
Figure 12.33 Digital Solutions for Biomarkers Market in Europe, 2021-2030 (USD Million)
Figure 12.34 Digital Solutions for Biomarkers Market in Asia-Pacific, 2021-2030 (USD Million)
Figure 12.35 Digital Solutions for Biomarkers Market in Middle East and North Africa, 2021-2030 (USD Million)
Figure 12.36 Digital Solutions for Biomarkers Market in Rest of the World, 2021-2030 (USD Million)
Figure 12.37 Global Digital Solutions for Biomarkers Market: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Figure 13.1 Digital Solutions for Biomarkers Market, 2021-2030: COVID-19 Impact Scenario (USD Billion)
Figure 13.2 Key Players in Digital Solutions for Biomarkers Domain to Target COVID-19 Pandemic
Figure 14.1 Concluding Remarks: Current Market Landscape-I
Figure 14.2 Concluding Remarks: Current Market Landscape-II
Figure 14.3 Concluding Remarks: Global Events Analysis
Figure 14.4 Concluding Remarks: Funding and Investments Analysis
Figure 14.5 Concluding Remarks: Partnerships and Collaborations
Figure 14.6 Concluding Remarks: Big Pharma Initiatives
Figure 14.7 Concluding Remarks: Market Forecast

List Of Tables

Table 4.1 Digital Solutions for Biomarkers: Information on Current Status and Launch Year
Table 4.2 Digital Solutions for Biomarkers: Information on Content of Solution
Table 4.3 Digital Solutions for Biomarkers: Information on Purpose of Solution and Type of Biomarker
Table 4.4 Digital Solutions for Biomarkers: Information on Target Indication(s) and Therapeutic Area
Table 4.5 Digital Solutions for Biomarkers: Information on Target Population and Prescription Requirement
Table 4.6 Digital Solutions for Biomarkers: List of Developers
Table 6.1 Digital Solutions for Biomarkers: List of Companies Profiled
Table 6.2 Acculi Labs: Company Overview
Table 6.3 Acculi Labs: Digital Solutions for Biomarkers Portfolio
Table 6.4 Acculi Labs: Recent Developments and Future Outlook
Table 6.5 Canary Health Technologies: Company Overview
Table 6.6 Canary Health Technologies: Digital Solutions for Biomarkers Portfolio
Table 6.7 Canary Health Technologies: Recent Developments and Future Outlook
Table 6.8 Empatica: Company Overview
Table 6.9 Empatica: Digital Solutions for Biomarkers Portfolio
Table 6.10 Empatica: Recent Developments and Future Outlook
Table 6.11 IXICO: Company Overview
Table 6.12 IXICO: Digital Solutions for Biomarkers Portfolio
Table 6.13 IXICO: Recent Developments and Future Outlook
Table 6.14 Kinsa: Company Overview
Table 6.15 Kinsa: Digital Solutions for Biomarkers Portfolio
Table 6.16 Kinsa: Recent Developments and Future Outlook
Table 6.17 Progentec Diagnostics: Company Overview
Table 6.18 Progentec Diagnostics: Digital Solutions for Biomarkers Portfolio
Table 6.19 Progentec Diagnostics: Recent Developments and Future Outlook
Table 6.20 Spirosure: Company Overview
Table 6.21 Spirosure: Digital Solutions for Biomarkers Portfolio
Table 6.22 Spirosure: Recent Developments and Future Outlook
Table 6.23 Vocalis Health: Company Overview
Table 6.24 Vocalis Health: Digital Solutions for Biomarkers Portfolio
Table 6.25 Vocalis Health: Recent Developments and Future Outlook
Table 8.1 List of Events related to Digital Solutions for Biomarkers
Table 9.1 Digital Solutions for Biomarkers: Funding and Investments, Information on Year of Investment, Type of Funding, Amount invested and Name of the Investor, 2012 - Q3 2020
Table 9.2 Digital Solutions for Biomarkers: Funding and Investments, Information on Year of Establishment, Location of Headquarters of Recipients, Type of Biomarker, and Therapeutic Area
Table 10.1 Digital Solutions for Biomarkers: List of Collaborations, 2014 - Q3 2020
Table 10.2 Digital Solutions for Biomarkers: Partnerships and Collaborations, Information on Type of Partner and Type of Agreement (Region-wise and Geography-wise), 2014 - Q3 2020
Table 16.1 Digital Solutions for Biomarkers: Distribution by Current Status
Table 16.2 Digital Solutions for Biomarkers: Distribution by Launch Year
Table 16.3 Digital Solutions for Biomarkers: Distribution by Content of Solution
Table 16.4 Digital Solutions for Biomarkers: Distribution by Purpose of Solution
Table 16.5 Digital Solutions for Biomarkers: Distribution by Type of Biomarker
Table 16.6 Digital Solutions for Biomarkers: Distribution by Purpose of Solution and Type of Biomarker
Table 16.7 Digital Solutions for Biomarkers: Distribution by Target Indication(s)
Table 16.8 Digital Solutions for Biomarkers: Distribution by Therapeutic Area
Table 16.9 Digital Solutions for Biomarkers: Distribution by Target Population
Table 16.10 Digital Solutions for Biomarkers: Distribution by Prescription Requirement
Table 16.11 Digital Solutions for Biomarkers Developers: Distribution by Year of Establishment
Table 16.12 Digital Solutions for Biomarkers Developers: Distribution by Company Size
Table 16.13 Digital Solutions for Biomarkers Developers: Distribution by Type of Business Model Used
Table 16.14 Digital Solutions for Biomarkers Developers: Distribution by Location of Headquarters
Table 16.15 Digital Solutions for Biomarkers Developers: Leading Developers Based on Number of Digital Solutions for Biomarkers
Table 16.16 4D Bubble Analysis: Analysis by Portfolio Strength, Type of Biomarker and Company Size
Table 16.17 Grid Representation: Analysis by Current Status, Content of Solution and Therapeutic Area
Table 16.18 Tree Map Representation: Analysis by Therapeutic Area and Company Size
Table 16.19 World Map Representation: Analysis by Location of Headquarters
Table 16.20 Current and Future Market Landscape Trends Analysis: Distribution by Current Status, Type of Biomarker and Therapeutic Area
Table 16.21 Global Events Analysis: Cumulative Half Year-Wise Trend, 2016 – H1 2021
Table 16.22 Global Events Analysis: Distribution by Event Platform
Table 16.23 Global Events Analysis: Distribution by Geography
Table 16.24 Global Events Analysis: Distribution by Location
Table 16.25 Global Events Analysis: Distribution by Type of Event
Table 16.26 Global Events Analysis: Most Active Event Organizers
Table 16.27 Global Events Analysis: Most Active Industry Players Based on Event Participation
Table 16.28 Global Events Analysis: Most Active Non-Industry Players Based on Event Participation
Table 16.29 Global Events Analysis: Distribution by Designations of Event Participants
Table 16.30 Funding and Investments Analysis: Distribution of Recipient Companies by Year of Establishment and Type of Funding
Table 16.31 Funding and Investments Analysis: Cumulative Year-wise Distribution of Funding Instances by Year, 2012 – Q3 2020
Table 16.32 Funding and Investment Analysis: Cumulative Amount Invested (USD Million), 2012 - Q3 2020
Table 16.33 Funding and Investments Analysis: Distribution of Instances by Type of Funding, 2012 - Q3 2020
Table 16.34 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding, 2012 - Q3 2020
Table 16.35 Funding and Investments Analysis: Year-Wise Distribution by Type of Funding and Funding Amount Invested, 2012 - Q3 2020 (USD Million)
Table 16.36 Funding and Investments Analysis: Summary of Amount Invested, 2012 - Q3 2020 (USD Million)
Table 16.37 Funding and Investments Analysis: Distribution of Instances by Type of Biomarker, 2012 - Q3 2020
Table 16.38 Funding and Investments Analysis: Distribution of Total Amount Invested by Type of Biomarker, 2012 – Q3 2020 (USD Million)
Table 16.39 Funding and Investments Analysis: Year-Wise Distribution of Instances by Type of Biomarker, 2012 – Q3 2020
Table 16.40 Funding and Investments Analysis: Cumulative Amount Invested by Type of Biomarker, 2012 - Q3 2020 (USD Million)
Table 16.41 Funding and Investments Analysis: Distribution of Instances by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Table 16.42 Funding and Investments Analysis: Distribution of Total Amount Invested by Therapeutic Area, 2012 – Q3 2020 (USD Million)
Table 16.43 Funding and Investment Analysis: Distribution by Geography
Table 16.44 Funding and Investment Analysis: Regional Distribution by Total Amount Invested, 2012 – Q3 2020 (USD Million)
Table 16.45 Funding and Investment Analysis: Most Active Players Based on Number of Funding Instances, 2012 – Q3 2020
Table 16.46 Funding and Investment Analysis: Most Active Players Based on Total Amount Raised (USD Million), 2012 – Q3 2020 (USD Million)
Table 16.47 Funding and Investment Analysis: Most Active Investors Based on Number of Funding Instances
Table 16.48 Funding and Investment Summary, 2012 – Q3 2020 (USD Million)
Table 16.49 Partnerships and Collaborations: Cumulative Year-Wise Trend, 2014 – Q3
Table 16.50 Partnerships and Collaborations: Distribution by Type of Partnership
Table 16.51 Partnerships and Collaborations: Year-Wise Trend by Type of Partnership
Table 16.52 Partnerships and Collaborations: Distribution by Type of Partnership and Company Size
Table 16.53 Partnerships and Collaborations: Distribution by Type of Partner
Table 16.54 Partnerships and Collaborations: Year-Wise Trend by Type of Partner
Table 16.55 Partnerships and Collaborations: Distribution by Type of Partner and Type of Partnership
Table 16.56 Partnerships and Collaborations: Distribution by Type of Partner and Company Size
Table 16.57 Partnerships and Collaborations: Distribution by Type of Biomarker
Table 16.58 Partnerships and Collaborations: Year-Wise Trend by Type of Biomarker
Table 16.59 Partnerships and Collaborations: Distribution by Type of Biomarker and Type of Partnership
Table 16.60 Partnerships and Collaborations: Distribution by Therapeutic Area
Table 16.61 Partnerships and Collaborations: Year-Wise Trend by Therapeutic Area
Table 16.62 Partnerships and Collaborations: Distribution by Therapeutic Area and Type of Partner
Table 16.63 Most Active Players: Distribution by Number of Partnerships
Table 16.64 Partnerships and Collaborations: Regional Distribution
Table 16.65 Partnerships and Collaborations: Country-wise Distribution
Table 16.66 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 16.67 Big Pharma Initiatives: Heat Map Distribution of Top Pharmaceutical Companies
Table 16.68 Big Pharma Initiatives: Distribution by Number of Clinical Trials
Table 16.69 Big Pharma Initiatives: Distribution by Number of Collaborations
Table 16.70 Big Pharma Initiatives: Distribution by Amount of Funding (USD Million)
Table 16.71 Big Pharma Initiatives: Distribution by Participation in Global Events
Table 16.72 Big Pharma Initiatives: Distribution by Number of Research Publications
Table 16.73 Overall Digital Solutions for Biomarkers Market: Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.74 Global Digital Solutions for Biomarkers Market: Distribution by Content of Solution, 2021 and 2030
Table 16.75 Digital Solutions for Biomarkers Market for Standalone Software Applications, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.76 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + AI Support), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.77 Digital Solutions for Biomarkers Market for Combination Offerings (Software Application + Device), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.78 Digital Solutions for Biomarkers Market for Other Content of Solutions, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.79 Global Digital Solutions for Biomarkers Market: Distribution by Purpose of Solution, 2021 and 2030
Table 16.80 Digital Solutions for Biomarkers Market for Diagnosis, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.81 Digital Solutions for Biomarkers Market for Early Screening, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.82 Digital Solutions for Biomarkers Market for Monitoring, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.83 Digital Solutions for Biomarkers Market for Predictive Insights, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.84 Global Digital Solutions for Biomarkers Market: Distribution by Type of Biomarker, 2021 and 2030
Table 16.85 Digital Solutions for Cognitive Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.86 Digital Solutions for Idiosyncratic Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.87 Digital Solutions for Physiological Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.88 Digital Solutions for Vocal Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.89 Digital Solutions for Other Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.90 Global Digital Solutions for Biomarkers Market: Distribution by Therapeutic Area, 2021 and 2030
Table 16.91 Digital Solutions for Biomarkers Market for Autoimmune Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.92 Digital Solutions for Biomarkers Market for Cardiovascular Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.93 Digital Solutions for Biomarkers Market for Infectious Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.94 Digital Solutions for Biomarkers Market for Mental Health Problems, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.95 Digital Solutions for Biomarkers Market for Neurological Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.96 Digital Solutions for Biomarkers Market for Respiratory Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.97 Digital Solutions for Biomarkers Market for Substance Use Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.98 Digital Solutions for Biomarkers Market for Other Disorders, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.99 Global Digital Solutions for Biomarkers Market: Distribution by Business Model, 2021 and 2030
Table 16.100 Digital Solutions for Biomarkers Market for B2B Model (Healthcare Providers, Payers, Employers and Pharmaceutical Companies), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.101 Digital Solutions for Biomarkers Market for B2C Model (Patients and Caregivers), Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.102 Global Digital Solutions for Biomarkers Market: Distribution by Geography, 2021 and 2030
Table 16.103 Digital Solutions for Biomarkers Market in North America, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.104 Digital Solutions for Biomarkers Market in Europe, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.105 Digital Solutions for Biomarkers Market in Asia-Pacific, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.106 Digital Solutions for Biomarkers Market in Middle East and North Africa, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.107 Digital Solutions for Biomarkers Market in Rest of the World, Conservative, Base and Optimistic Scenarios, 2021-2030 (USD Million)
Table 16.108 Global Digital Solutions for Biomarkers Market, Conservative, Base and Optimistic Scenarios, 2021-2030: Conservative, Base and Optimistic Scenarios, 2021, 2025 and 2030 (USD Million)
Table 16.109 Digital Solutions for Biomarkers Market, 2021-2030: COVID-19 Impact Scenario (USD Billion)

List Of Companies

The following companies and organizations have been mentioned in the report.

  1. 5AM Ventures
  2. AAF Management
  3. Accel Diagnostics
  4. Accelmed Growth Partners
  5. Acculi Labs
  6. ActiGraph
  7. AiCure
  8. Air Force Research Laboratory
  9. Akili Interactive
  10. A-klinikka Oy
  11. Albion Capital
  12. Alector
  13. AliveCor
  14. Alpana Ventures
  15. Altoida
  16. Alumni Ventures Group
  17. Americans superenkeleiltä
  18. Amgen
  19. Amgen Ventures
  20. aMoon
  21. Apple
  22. Applied Morphomics
  23. Arboretum Ventures
  24. Asahi Kasei
  25. Baillie Gifford
  26. Baird Capital
  27. Battery Ventures
  28. Bayer
  29. Ben Franklin Technology Partners of Northeastern Pennsylvania
  30. BioBeats
  31. Biogen
  32. Biomatics Capital
  33. Biomedical Advanced Research and Development Authority
  34. Bio-Rad Laboratories
  35. Biosensics
  36. BizTech
  37. BlackThorn Therapeutics
  38. Blue Water Life Science Fund
  39. Bridge Builders Collaborative
  40. Bristol-Myers Squibb
  41. Brooklands Capital Strategies
  42. Burns & Stowers Investments
  43. byFounders
  44. Byteflies
  45. CAIRE
  46. Canary Health Technologies
  47. Canepa Advanced Healthcare Fund
  48. Capital Partners
  49. Cardiac Insight
  50. CareFirst BlueCross BlueShield
  51. Carmen Innovations
  52. Castor Ventures
  53. Cerora
  54. CincyTech
  55. CLSA
  56. Clue
  57. Cogito
  58. Cognetivity Neurosciences
  59. Cogstate
  60. Cohero Health
  61. Connetic Ventures
  62. Contiguity
  63. CoreSyte
  64. Corti
  65. Creative Destruction Lab
  66. Crush The Curve Idaho
  67. Dale Ventures
  68. DG Daiwa Ventures
  69. DigiBio
  70. Digital Health Ecosystem Wales
  71. Eccrine Systems
  72. EDBI
  73. Eisai
  74. EIT Health
  75. Elektra Labs
  76. Eli Lilly
  77. Empatica
  78. Endeavor Catalyst
  79. EU Executive Agency for SMEs (EASME)
  80. Eyelogics
  81. Fearless Ventures
  82. FeetMe
  83. Tesi
  84. First Star Ventures
  85. FirstMark Capital
  86. FitBit
  87. Flying Health
  88. Forerunner Ventures
  89. Founder Collective
  90. FYRFLY Venture Partners
  91. GE Healthcare
  92. GE Ventures
  93. GlaxoSmithKline
  94. Goldman Sachs Growth Equity (GS Growth)
  95. Gradient Ventures
  96. Grey Sky Venture Partners
  97. GSR Ventures
  98. Happify Health
  99. Healios
  100. Healthbox
  101. Healthymize
  102. Hearst Ventures
  103. Heartcore Capital
  104. Hikma Pharmaceuticals
  105. Hikma Ventures
  106. Huma
  107. Human API
  108. i2E
  109. IA Ventures
  110. Idinvest Partners
  111. Imagia
  112. IMINT Image Intelligence
  113. imvaria
  114. Indie Health
  115. Innogest Capital
  116. Invitalia Ventures
  117. Iratel Ventures
  118. Israel Innovation Authority
  119. IXICO
  120. Jana Care
  121. Janssen Pharmaceuticals
  122. JAZZ Venture Partners
  123. Johnson & Johnson
  124. Karate Health
  125. Kinsa
  126. Kleiner Perkins
  127. Kontigo Care
  128. Kryo
  129. LaunchCapital
  130. Lifeline Ventures
  131. LifeOmic
  132. LupusCorner
  133. Lysol
  134. MoodNetwork
  135. Maxim Integrated Products
  136. Mayo Clinic
  137. Medidata Solutions
  138. Medopad
  139. MedScaler
  140. Merck
  141. Merck Ventures
  142. Mindstrong Health
  143. MIT Media Lab
  144. MP Healthcare Venture Management
  145. MSD Capital
  146. Nanowear
  147. NASCAR
  148. National Health Service
  149. National Institute of Allergy and Infectious Diseases
  150. National Institute on Drug Abuse (NIDA)
  151. National Institutes of Health (NIH)
  152. National Basketball Association (NBA)
  153. Neoteny 4
  154. NeuraMetrix
  155. Neurocast
  156. NeuroLex Labs
  157. Neurotrack
  158. New Leaf Venture Partners
  159. NEXT VENTŪRES
  160. NGK Spark Plugs
  161. NMC Health
  162. NMC Lifesciences
  163. Nordic Makers
  164. Novartis
  165. Novatio Ventures
  166. N-Strategy Consulting Services
  167. NWS Holdings
  168. OCA Ventures
  169. Ohio Innovation Fund
  170. Oklahoma Medical Research Foundation
  171. Olive Healthcare
  172. Omidyar Technology Ventures
  173. OpenView Venture Partners
  174. Orikami
  175. Oura
  176. Pacific Health Ventures
  177. Palisades Growth Capital
  178. Pear Therapeutics
  179. PeerWell
  180. Pfizer
  181. Philips
  182. Plains Venture Partners
  183. PM360
  184. Polytech Ventures
  185. Pritzker Group
  186. Pritzker Group Venture Capital
  187. Progentec Diagnostics
  188. Propeller Health
  189. Proxy Ventures
  190. PureTech Health
  191. Quanterix
  192. RAE Health
  193. RavenOye
  194. Readout Health
  195. ResApp Health
  196. Rett Syndrome Research Trust
  197. Revera
  198. Roche
  199. Romulus Capital
  200. Sage Bionetworks
  201. Salesforce Ventures
  202. Sanofi
  203. Science 37
  204. Senza
  205. Sesame Street
  206. Shanghai Fosun Pharmaceutical
  207. Silicon Valley Bank
  208. SIME Diagnostics
  209. Simul Investments
  210. Singtel Innov8
  211. Small Business Research Initiative (SBRI) Healthcare
  212. Sonde Health
  213. South Valley Angels
  214. Spice Capital
  215. Spirosure
  216. SpringRock Ventures
  217. Stanford University
  218. Startup Basket
  219. StartUp Health
  220. State of Colorado
  221. Sway Medical
  222. Syneos Health
  223. Takeda Pharmaceuticals
  224. Tarilian Laser Technologies
  225. TechniPlast
  226. Teladoc Health
  227. Temasek
  228. National Center for Women & Information Technology (NCWIT)
  229. Tribeca Venture Partners
  230. Trustbridge
  231. U-Care Medical
  232. United States Air Force
  233. University College London
  234. University of California, San Francisco (UCSF)
  235. University of Cincinnati
  236. University of Witwatersrand
  237. Vala Sciences
  238. Venture Kick
  239. Verily Life Sciences
  240. Vignet
  241. VI Partners
  242. Vivante Health
  243. Vivo India
  244. Vivoryon Therapeutics
  245. VivoSense
  246. Vocalis Health
  247. Vyaire Medical
  248. Welsh Government
  249. West Virginia University Rockefeller Neuroscience Institute
  250. Winterlight Labs
  251. Women’s National Basketball Association (WNBA)
  252. YouGene
  253. ZenStone Venture Capital

Segmentation

The USD 22.6 billion (by 2030) financial opportunity within the digital solutions for biomarkers market has been analyzed across the following segments:

  • Content of Solution
    • Software Application + AI Support
    • Software Application + Device
    • Standalone Software Application
    • Other Contents of Solutions
  • Purpose of Solution
    • Diagnosis
    • Early Screening
    • Monitoring
    • Predictive Insights
  • Type of Biomarker
    • Cognitive Biomarkers
    • Idiosyncratic Biomarkers
    • Physiological Biomarkers
    • Vocal Biomarkers
    • Other Biomarkers
  • Therapeutic Areas
    • Autoimmune Disorders 
    • Cardiovascular Disorders 
    • Infectious Disorders
    • Mental Health Problems
    • Neurological Disorders
    • Respiratory Disorders
    • Substance Use Disorders
    • Others
  • Business Model
    • Business to Business (Healthcare Providers, Payers, Employers and Pharmaceutical Companies)
    • Business to Consumer (Patients and Caregivers)
  • Key Geographical Regions 
    • North America
    • Europe
    • Asia-Pacific
    • Middle East and North Africa (MENA)
    • Rest of the world

PRICING DETAILS

USD 5,499

This license grants the right of use of the purchased report to a single recipient only (normally the person who buys the report). You may access the material on your computer, as and when required, for your own personal use. You may also print read more

This license grants the right of use of the purchased report by the employees of a business unit at a particular site/office location. The report may be accessed on the computer of any employee within the business unit. You may also print multiple read more

This license entitles the buyer of the report to share, distribute the report (either full or in part) with other employees of the same firm/enterprise. The report may be accessed by any employee of the enterprise and there is no limit on the read more

Discounts available for multiple report purchases
sales@rootsanalysis.com